Survodutide (TFA)

• UNSPSC Description:

  Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1].

• Target Antigen:

  GCGR; GLP Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/survodutide-tfa.html

• Purity:

  99.62

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mL

• Smiles:

  [Survodutide (TFA)]

• Molecular Weight:

  4231.62 (free base)

• References & Citations:

  [1]Tina Zimmermann, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec:66:101633.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 3